NeuBase Therapeutics, Inc. (NBSE)

0.9900 +0.0300 (+3.13%) As of 12:26PM EDT. Market open.

NeuBase Therapeutics, Inc.

350 Technology Drive
Third Floor
Pittsburgh, PA 15219
United States
646 450 1790
https://www.neubasetherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 33

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Dietrich A. Stephan Ph.D.	Founder, Pres, CEO & Chairman	713.83k	N/A	1970
Dr. William Roland Mann MBA, Ph.D.	Chief Operating Officer	470.4k	N/A	1960
Mr. Todd P. Branning	Chief Financial Officer	N/A	N/A	1971
Dr. Anthony Rossomando Ph.D.	Chief Technology Officer	N/A	N/A	N/A
Dr. Curt Bradshaw Ph.D.	Chief Scientific Officer	N/A	N/A	1965
Mr. Alan Scrivner J.D.	VP of IP & Legal	N/A	N/A	N/A
Ms. Shannon McCarthy	Chief People Officer	N/A	N/A	N/A
Dr. Sandra Rojas-Caro M.D.	Head of R&D and Chief Medical Officer	N/A	N/A	1970
Dr. Robert J. Zamboni Ph.D.	Chief of Preclinical Devel. & Member of Scientific Advisory Board	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Corporate governance

NeuBase Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2022 is 10. The pillar scores are Audit: 10; Board: 9; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.